Jose Luis Ramirez

Jose Luis Ramirez

Auto-generated profile, based on publicly available information

Jose Luis Ramirez

Catalan Institute of Oncology, Badalona, Spain

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Lung Cancer
Verified
Journal Article
Closed access
ECEnric Carcereny
Enric Carcereny
JRJose Luis Ramirez
Jose Luis Ramirez
MSMaria Sanchez-Ronco
Maria Sanchez-Ronco
DIDolores Isla
Dolores Isla
MCManuel Cobo
Manuel Cobo
RRRafael Rosell
Rafael Rosell

20 June 2006 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DIDolores Isla
Dolores Isla
FSF. Salazar
F. Salazar
JRJ. Ramirez
J. Ramirez
MRM. Sanchez Ronco
M. Sanchez Ronco
MCManuel Cobo
Manuel Cobo
Rafael RosellRafael Rosell
Rafael Rosell
7056 Background: CHFR (checkpoint with forkhead-associated and ring finger) regulates a prophase delay in cells exposed to agents that disrupt microtubules. Epigenetic inactivation of CHFR is a frequent event in human tumors, leading to impaired checkpoint function and enhanced sensitivity to docetaxel. We hypothesized that serum DNA methylation of CHFR could be a predictor of longer survival in p treated with doc/cis. Methods: Sodium bisulfite modified serum DNAwas used as the template for methylation-specific PCR assay. DNA was obtained from 600 doc/cis-treated stage IV NSCLC p. Results: Preliminary data on 301 p is available. The frequency of CHFR hypermethylation was 32.6%. There was no association between methylation and performance status (PS), age, gender, histology, response, 14–3-3σ serum DNA methylation, polymorphisms in lymphocyte DNA (ERCC1 118 C/T, ERCC1 C8092A, XRCC3 241 ThrMet), or tumor ERCC1 mRNA levels. Overall, there was a tendency to better median survival (MS) for p with methylated CHFR. In p with PS 0, MS was 33 months (m) for 41 p with methylated CHFR and 12 m for 64 p with unmethylated CHFR (P = 0.23). In p >66 years (y), MS was not reached for 31 p with methylated CHFR and 9.6 m for 80 p with unmethylated CHFR (P = 0.01), while in p <66 y, MS was 9.4 m for 67 p with methylated CHFR and 10 m for 123 p with unmethylated CHFR (P = 0.62). p with both 14–3-3σ and CHFR methylation showed a tendency to longer survival. Final data on 600 p will be presented. Conclusions: Early findings indicate that CHFR methylation in elderly p predicts a significant survival benefit in doc/cis-treated NSCLC. No significant financial relationships to disclose.